Ocular Therapeutix™ To Report Second Quarter 2022 Financial Results
July 25 2022 - 8:00AM
Business Wire
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical
company focused on the formulation, development, and
commercialization of innovative therapies for diseases and
conditions of the eye, today announced that it will report second
quarter ended June 30, 2022 financial results after the close on
Monday, August 8, 2022. Following distribution of the earnings
release via wire services, the Ocular Therapeutix management team
will host a live conference call and webcast at 4:30 p.m. Eastern
Time to review the Company’s financial results and provide a
general business update.
The live webcast can be accessed by visiting the Investors
section of the Company’s website at investors.ocutx.com. Please
connect at least 15 minutes prior to the live webcast to ensure
adequate time for any software download that may be needed to
access the webcast. Alternatively, please call (800) 715-9871
(U.S.) or (646) 307-1963 (International) to listen to the live
conference call. The conference ID number for the live call will be
9296568. A replay of the webcast will be available on the Company’s
website for 90 days following the live call.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused
on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye using
its proprietary bioresorbable hydrogel-based formulation
technology. Ocular Therapeutix’s first commercial drug product,
DEXTENZA®, is an FDA-approved corticosteroid for the treatment of
ocular inflammation and pain following ophthalmic surgery and
ocular itching associated with allergic conjunctivitis. Ocular
Therapeutix’s earlier stage development assets include: OTX-TKI
(axitinib intravitreal implant), currently in Phase 1 clinical
trials for the treatment of wet AMD and other retinal diseases;
OTX-TIC (travoprost intracameral implant), currently in a Phase 2
clinical trial for the treatment of primary open-angle glaucoma or
ocular hypertension; and OTX-CSI (cyclosporine intracanalicular
insert) for the chronic treatment of dry eye disease and OTX-DED
(dexamethasone intracanalicular insert) for the short-term
treatment of the signs and symptoms of dry eye disease, both of
which have completed Phase 2 clinical trials. Ocular Therapeutix's
first product, ReSure® Sealant, is an FDA-approved device to
prevent wound leaks in corneal incisions following cataract
surgery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220725005204/en/
Investors Ocular Therapeutix Donald Notman Chief
Financial Officer dnotman@ocutx.com
or
ICR Westwicke Chris Brinzey, 339-970-2843 Managing Director
chris.brinzey@westwicke.com
Media Ocular Therapeutix Scott Corning Senior Vice
President, Commercial scorning@ocutx.com
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Apr 2023 to Apr 2024